Large Molecule Bioanalysis done differently

To help you achieve more.

BioAgilytix has evolved the model for partnership in large molecule bioanalysis to benefit our customers and the patients they serve.

Services Delivered Scientist to Scientist

Our fully integrated GxP services are driven by your assay requirements and delivered by our veteran scientists – collaboratively, accurately, and on time.

biomarkers

Biomarkers

immunogenicity

Immunogenicity

pharmacokinetics

Pharmacokinetics (PK)

cell-based-assays

Cell-Based Assays

Solutions Enabled by World-Leading Expertise

Our team is comprised of recognized experts in effectively navigating complex and evolving opportunities for biotherapeutics innovation.

biosimilars

Biosimilars

gene-therapy

Gene Therapy

antibody-drug-conjugates

Antibody Drug Conjugates (ADCs)

immuno-oncology

Immuno-oncology

The Bioagilytix Perspective

Explore the BioAgilytix way of thinking. Visit our Resource Center to learn more about our scientists’ expertise through case studies, blogs, industry articles and other scientific resources.

resource center

Visit Resource Center

usa europe labs

Advanced facilities to support all phases of large molecule global studies.

    LinkedIn Company Updates

  • 1 Day Agoview on linkedin

    BioAgilytix

    We are excited to announce that our USA headquarters will be expanding again, this time by an additional 21,000+ square feet. The expansion will further grow capacity for all of our bioanalytical services and support our growing team: https://lnkd.in/e6isdmd

  • 1 Day Agoview on linkedin

    BioAgilytix

    BioAgilytix Europe is seeking a Data Controller to support verification of study data in close collaboration with our laboratory and quality assurance staff. If you are interested in joining our team in Hamburg, apply today: https://lnkd.in/egCYZ_Z

  • 2 Days Agoview on linkedin

    BioAgilytix

    Stanford University School of Medicine researchers have demonstrated that gene therapy can be effective without causing an autoimmune reaction to the normal protein, which the patient's immune system is encountering for the first time: https://lnkd.in/e9F7-QD via ScienceDaily